Status:
RECRUITING
eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
Fox Chase Cancer Center
National Cancer Institute (NCI)
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This randomized non-inferiority study will use a 2x2 design where traditional standard-of-care pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor are re...
Detailed Description
Germline cancer genetic testing has become a standard evidence-based practice, with established risk reduction and cancer screening guidelines for genetic carriers. Access to genetic specialists is li...
Eligibility Criteria
Inclusion
- 18 years of age or older
- Speak and understand English
- Male or Female
- No prior germline genetic testing
- Meet current National Comprehensive Cancer Network (NCCN) guidelines for germline genetic testing
Exclusion
- Communication difficulties such as:
- Uncorrected or uncompensated hearing and/or vision impairment
- Uncorrected or uncompensated speech defects
- Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks
Key Trial Info
Start Date :
September 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05427240
Start Date
September 28 2022
End Date
January 1 2026
Last Update
November 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104